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Despite being available for almost 70 years, we are only now beginning to understand the mechanism of action of glucocorticoids, a class of drugs that are essential in the treatment of rheumatoid arthritis (RA). In a new article, Koenen et al. 1 use a range of elegant in vivo approaches to investigate how glucocorticoids reduce joint inflammation in the serum transfer-induced arthritis (STIA) model. Bone marrow chimaeras (generated by irradiating mice to destroy immune cells and then using donor cells to repopulate the marrow) and inducible genetic deletion of NR3C1 (which encodes the glucocorticoid receptor) using a tamoxifen-inducible Cre-lox system enabled mice to be generated with selective deletion of the glucocorticoid receptor in either the haematopoietic or stromal compartment. Absence of the glucocorticoid receptor in haematopoietic cells had no effect on the ability of dexamethasone to suppress joint swelling and inflammation. However, absence of the glucocorticoid receptor in the stromal compartment rendered mice unresponsive to the effects of the glucocorticoid dexamethasone on joint inflammation. This work follows on from the study of an alternative mouse model of joint inflammation termed adjuvant-induced arthritis (AIA) 2 . Interestingly, in AIA mice the antiinflammatory effects of glucocorticoids were dependent on the presence of the glucocorticoid receptor in T cells, in which type 17 responses seemed to be major targets. In this model, there seemed to be no contribution from glucocorticoid receptors present in the stroma. The situation is further complicated by findings from other inflammatory models, which suggest that glucocorticoid receptors within macrophages are crucial to the mechanism of action of glucocorticoids 3 . These findings highlight the fact that although glucocorticoids have similar therapeutic effects in different inflammatory models, these effects might be mediated by different cell types. An unresolved question is how each of these mouse models translates into the clinical situation of RA and related joint diseases.
Although not traditionally thought of as a major target of glucocorticoids, the stroma is now implicated as a target of glucocorticoid action in inflammatory arthritis. Mice with
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Using mice with targeted deletion of the glucocorticoid receptor, a new study has examined the cell types that mediate the anti-arthritic effects of therapeutic glucocorticoids. Surprisingly , in the serum transferinduced arthritis model, glucocorticoids target stromal cells rather than immune cells. deletion of the glucocorticoid receptors in chondrocytes have exaggerated inflammation in both the AIA and STIA models, highlighting a possible anti-inflammatory role for chondrocyte glucocorticoid signalling in arthritis 4 . Somewhat paradoxically, glucocorticoid signalling in osteoblasts seems to be pro-inflammatory with blockade of the glucocorticoid receptor resulting in reduced inflammation in STIA mice 5 . In the study by Koenen et al. 1 the stromal cells seem to regulate inflammation by polarizing macrophages towards a suppressive phenotype, characterized by increased efferocytosis and expression of anti-inflammatory markers. How chondrocytes or osteoblasts affect inflammation is not clear. These results collectively indicate that several stromal cell types (synovial fibroblasts, chondrocytes and osteoblasts), in addition to immune cells, can mediate the effects of glucocorticoids on joint inflammation (Fig. 1 ).
An additional level of regulation of glucocorticoid action is the glucocorticoid metabolizing enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This enzyme amplifies glucocorticoid signalling through the local activation of glucocorticoids from inactive precursors, and is critical to the conversion of inactive glucocorticoids such as cortisone and prednisone to their active counterparts, cortisol and prednisolone. Importantly, 11β-HSD1 does not meta bolize dexamethasone. Mice defective in 11β-HSD1 develop exaggerated joint inflammation in acute and chronic models of arthritis 6, 7 . 11β-HSD1 activity within macrophages seems to be critical in restraining inflammation in these models 8 . It would be interesting to know whether the responses detected by Koenen et al. 1 with dexamethasone are similar using glucocorticoids that are regulated by 11β-HSD1 such as those typically used to treat patients with RA (cortisone and prednisone).
The novel finding that the stroma could be an important target opens up the prospect of developing medications that have the beneficial anti-inflammatory effects of glucocorticoids without the adverse effects. Early attempts to develop more selective glucocorticoids, known as selective glucocorticoid receptor agonists (SEGRAs), revolved around the notion that the beneficial effects of glucocorticoids were a result of the monomeric glucocorticoid receptor interfering with proinflammatory signalling pathways (termed repression), whereas adverse effects were a the stroma is now implicated as a target of glucocorticoid action in inflammatory arthritis result of the glucocorticoid receptor binding as a dimer to DNA (termed activation) 9 . Koenen et al. 1 examined this distinction by using mice in which the glucocorticoid receptor was unable to form a dimer and as such could only 'repress' and not 'activate' . They found that, although the monomer was able to suppress pro-inflammatory cytokines such as TNF, IL-1β and IFNγ, the ability of the glucocorticoid receptor to dimerize was essential for the anti-inflammatory effects of glucocorticoids. This finding illustrates that the simplistic view of repression being good and activation being bad is not tenable as a basis for developing SEGRAs. So, should SEGRAs be developed on the basis of selective targeting of stromal cells instead? Perhaps tempering enthusiasm for a stromal-targeted glucocorticoid-like therapy is the fact that the most prominent adverse effects of glucocorticoids, such as osteoporosis, osteonecrosis, myopathy and skin thinning, manifest via the functions of stromal cells 10 .
A persistent question is whether these findings are applicable to people with RA and related conditions. Whether animal models of arthritis individually or collectively truly mimic the biology of patients in the clinic is unclear. It is possible that the most important targets of glucocorticoids change during the clinical course of inflammatory arthritis. The animal models of arthritis employed so far focus on the short-term relief of joint inflammation by glucocorticoids rather than long-term effects on disease activity and joint integrity. Unfortunately, the clever experimental techniques employed by Koenen et al. 1 cannot be used in humans to address the extent to which glucocorticoids target the stroma. Novel translational approaches are needed to study the actions of glucocorticoids in patients with RA. Without improved approaches to target glucocorticoids selectively to either the stromal or classical immune cells in patients with inflammatory arthritis, it will be difficult to define the relative contributions of each of these.
Koenen et al. 1 have uncovered facets of glucocorticoid action that suggest new options to optimize their effectiveness. Despite their vintage, glucocorticoids continue to surprise us regarding how they work.
